Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval

Holly Geyer, Keith Cannon, Emily Knight, Veena Fauble, John K Camoriano, Robyn Emanuel, Raoul Tibes, Ruben Mesa

Research output: Contribution to journalArticle

17 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalLeukemia and Lymphoma
Volume55
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Pyrazoles
Janus Kinases
Drug Approval
Primary Myelofibrosis
United States Food and Drug Administration
Antineoplastic Agents
Therapeutics
INCB018424

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Ruxolitinib in clinical practice for therapy of myelofibrosis : Single USA center experience following Food and Drug Administration approval. / Geyer, Holly; Cannon, Keith; Knight, Emily; Fauble, Veena; Camoriano, John K; Emanuel, Robyn; Tibes, Raoul; Mesa, Ruben.

In: Leukemia and Lymphoma, Vol. 55, No. 1, 01.2014, p. 195-197.

Research output: Contribution to journalArticle

Geyer, Holly ; Cannon, Keith ; Knight, Emily ; Fauble, Veena ; Camoriano, John K ; Emanuel, Robyn ; Tibes, Raoul ; Mesa, Ruben. / Ruxolitinib in clinical practice for therapy of myelofibrosis : Single USA center experience following Food and Drug Administration approval. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 1. pp. 195-197.
@article{a83434a92386469a862d7ed3fedc3d4d,
title = "Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval",
author = "Holly Geyer and Keith Cannon and Emily Knight and Veena Fauble and Camoriano, {John K} and Robyn Emanuel and Raoul Tibes and Ruben Mesa",
year = "2014",
month = "1",
doi = "10.3109/10428194.2013.789507",
language = "English (US)",
volume = "55",
pages = "195--197",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Ruxolitinib in clinical practice for therapy of myelofibrosis

T2 - Single USA center experience following Food and Drug Administration approval

AU - Geyer, Holly

AU - Cannon, Keith

AU - Knight, Emily

AU - Fauble, Veena

AU - Camoriano, John K

AU - Emanuel, Robyn

AU - Tibes, Raoul

AU - Mesa, Ruben

PY - 2014/1

Y1 - 2014/1

UR - http://www.scopus.com/inward/record.url?scp=84887954865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887954865&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.789507

DO - 10.3109/10428194.2013.789507

M3 - Article

C2 - 23647081

AN - SCOPUS:84887954865

VL - 55

SP - 195

EP - 197

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -